Latest Pharma Insights
Medtech Majors Favor Spin-Offs And Tuck-Ins Over Big Buys On Q3 Earnings Calls
Medtech deal value through September has already overtaken all of 2025. Yet on third-quarter calls, the largest companies talked more about separating businesses, finishing integrations and keeping new purchases small than about the next big buy.
Medtech Insight - November 13, 2026
Medtech deal value through September has already overtaken all of 2025. Yet on third-quarter calls, the largest companies talked more about separating businesses, finishing integrations and keeping new purchases small than about the next big buy.
Medtech Insight - November 13, 2026
CMS Expands Outpatient Surgery Coverage, Approves Nine Devices in 2027 Hospital Payment Final Rule
CMS's 2027 OPPS final rule expands outpatient procedure coverage, approves nine medical devices for transitional pass-through payments, and establishes a new payment framework for software-based diagnostic services. The rule also revises some imaging reimbursement policies.
Medtech Insight - November 13, 2026
CMS's 2027 OPPS final rule expands outpatient procedure coverage, approves nine medical devices for transitional pass-through payments, and establishes a new payment framework for software-based diagnostic services. The rule also revises some imaging reimbursement policies.
Medtech Insight - November 13, 2026
Executives On The Move: Three CMOs And One CEO Among This Week’s Changes
Recent industry moves include three senior appointments at Juniper Biosciences, leadership changes at Bristol Myers Squibb and new C-suite hires at Nurix Therapeutics and Allucent.
Scrip - November 13, 2026
Recent industry moves include three senior appointments at Juniper Biosciences, leadership changes at Bristol Myers Squibb and new C-suite hires at Nurix Therapeutics and Allucent.
Scrip - November 13, 2026
Gedeon Richter Urges Countries To Recalibrate Biosimilar Tenders, Citing Supply Shortfalls
Gedeon Richter says it will limit how many molecules it develops at once unless European biosimilar pricing stabilizes, as biotech revenue rose 34% in Q3 2026.
Generics Bulletin - November 13, 2026
Gedeon Richter says it will limit how many molecules it develops at once unless European biosimilar pricing stabilizes, as biotech revenue rose 34% in Q3 2026.
Generics Bulletin - November 13, 2026
Sandoz And Lupin Roll Out European Ranibizumab
The launch of the Ranluspec ranibizumab biosimilar to Lucentis fills a gap in Sandoz’s portfolio while giving Lupin access to the European market.
Generics Bulletin - November 13, 2026
The launch of the Ranluspec ranibizumab biosimilar to Lucentis fills a gap in Sandoz’s portfolio while giving Lupin access to the European market.
Generics Bulletin - November 13, 2026
Jefferies 2026 Preview: Dealmaking Strong But China Curbs Will Concern
Biopharma deals and financings, US-China friction and the coming of age of novel modalities will be among talking points at the Jefferies Global Healthcare Conference in London.
Scrip - November 13, 2026
Biopharma deals and financings, US-China friction and the coming of age of novel modalities will be among talking points at the Jefferies Global Healthcare Conference in London.
Scrip - November 13, 2026
Special Episode: Topspin and Why Product Demand, Not Coverage, Drives Formulary Power
Formulary placement is rented real estate: PBMs keep products that generate prescription demand. Rebates mean little without volume, so pharma should start market access thinking in Phase II, not after filing.
In Vivo - November 13, 2026
Formulary placement is rented real estate: PBMs keep products that generate prescription demand. Rebates mean little without volume, so pharma should start market access thinking in Phase II, not after filing.
In Vivo - November 13, 2026
Preventive Medicine’s Bottleneck Is Not Science – It’s Economics
Gene therapies that could prevent or cure disease in a single dose are drawing billions in investment, but US and European health systems are built to pay for chronic care over a lifetime. Unless payers rethink incentives for one-time treatment, economics may set the pace more than science.
In Vivo - November 13, 2026
Gene therapies that could prevent or cure disease in a single dose are drawing billions in investment, but US and European health systems are built to pay for chronic care over a lifetime. Unless payers rethink incentives for one-time treatment, economics may set the pace more than science.
In Vivo - November 13, 2026
Executives On The Move: Three CMOs And One CEO Among This Week’s Changes
Recent industry moves include three senior appointments at Juniper Biosciences, leadership changes at Bristol Myers Squibb and new C-suite hires at Nurix Therapeutics and Allucent.
Scrip - November 13, 2026
Recent industry moves include three senior appointments at Juniper Biosciences, leadership changes at Bristol Myers Squibb and new C-suite hires at Nurix Therapeutics and Allucent.
Scrip - November 13, 2026
Jefferies 2026 Preview: Dealmaking Strong But China Curbs Will Concern
Biopharma deals and financings, US-China friction and the coming of age of novel modalities will be among talking points at the Jefferies Global Healthcare Conference in London.
Scrip - November 13, 2026
Biopharma deals and financings, US-China friction and the coming of age of novel modalities will be among talking points at the Jefferies Global Healthcare Conference in London.
Scrip - November 13, 2026
Medtech Majors Favor Spin-Offs And Tuck-Ins Over Big Buys On Q3 Earnings Calls
Medtech deal value through September has already overtaken all of 2025. Yet on third-quarter calls, the largest companies talked more about separating businesses, finishing integrations and keeping new purchases small than about the next big buy.
Medtech Insight - November 13, 2026
Medtech deal value through September has already overtaken all of 2025. Yet on third-quarter calls, the largest companies talked more about separating businesses, finishing integrations and keeping new purchases small than about the next big buy.
Medtech Insight - November 13, 2026
CMS Expands Outpatient Surgery Coverage, Approves Nine Devices in 2027 Hospital Payment Final Rule
CMS's 2027 OPPS final rule expands outpatient procedure coverage, approves nine medical devices for transitional pass-through payments, and establishes a new payment framework for software-based diagnostic services. The rule also revises some imaging reimbursement policies.
Medtech Insight - November 13, 2026
CMS's 2027 OPPS final rule expands outpatient procedure coverage, approves nine medical devices for transitional pass-through payments, and establishes a new payment framework for software-based diagnostic services. The rule also revises some imaging reimbursement policies.
Medtech Insight - November 13, 2026
Perrigo Sizing Up Growth Drivers As Retailers Take ‘Measured Approach’ On Cough/Cold Sales
E-commerce sales of all products and marketing OTC drugs for GLP-1 users noted as key growth drivers but “more measured retailer inventory positioning ahead of cough and cold season” temper Perrigo’s Q4 outlook.
HBW Insight - November 12, 2026
E-commerce sales of all products and marketing OTC drugs for GLP-1 users noted as key growth drivers but “more measured retailer inventory positioning ahead of cough and cold season” temper Perrigo’s Q4 outlook.
HBW Insight - November 12, 2026
MPs Call UK Cosmetics Regulation A ‘Confusing Mess’; CTPA Disagrees
A UK parliamentary committee calls for reforms to cosmetic regulation while lumping aesthetic procedures in with cosmetic products.
HBW Insight - November 12, 2026
A UK parliamentary committee calls for reforms to cosmetic regulation while lumping aesthetic procedures in with cosmetic products.
HBW Insight - November 12, 2026
IQVIA Consumer Health: GLP-1s Could Usher In ‘Golden Age’ For Industry
Self-pay spending on GLP-1 weight-loss drugs in Germany is now more than 20 times the size of the pharmacy OTC weight-loss market. IQVIA Consumer Health says the needs those users develop are a major opportunity for consumer health brands.
HBW Insight - November 12, 2026
Self-pay spending on GLP-1 weight-loss drugs in Germany is now more than 20 times the size of the pharmacy OTC weight-loss market. IQVIA Consumer Health says the needs those users develop are a major opportunity for consumer health brands.
HBW Insight - November 12, 2026
MHRA Brands Voy’s Supplement Ads ‘Disingenuous’ As ASA Finds They Promoted Oral GLP-1
Two advertising rulings against online pharmacy Voy show how quickly marketers are trying to trade on the launch of the first oral GLP-1 tablet in the UK.
HBW Insight - November 12, 2026
Two advertising rulings against online pharmacy Voy show how quickly marketers are trying to trade on the launch of the first oral GLP-1 tablet in the UK.
HBW Insight - November 12, 2026
Preparing For Next Pandemic, FDA Offers Guidance For Validating Emergency Authorization Tests
FDA finalizes guidance on validating diagnostic tests for emerging pathogens during declared emergency. Allows developers to send some data after submission and use synthetic samples early in an outbreak; also covers study design, home-use testing and more.
HBW Insight - November 12, 2026
FDA finalizes guidance on validating diagnostic tests for emerging pathogens during declared emergency. Allows developers to send some data after submission and use synthetic samples early in an outbreak; also covers study design, home-use testing and more.
HBW Insight - November 12, 2026
Gedeon Richter Urges Countries To Recalibrate Biosimilar Tenders, Citing Supply Shortfalls
Gedeon Richter says it will limit how many molecules it develops at once unless European biosimilar pricing stabilizes, as biotech revenue rose 34% in Q3 2026.
Generics Bulletin - November 13, 2026
Gedeon Richter says it will limit how many molecules it develops at once unless European biosimilar pricing stabilizes, as biotech revenue rose 34% in Q3 2026.
Generics Bulletin - November 13, 2026
Sandoz And Lupin Roll Out European Ranibizumab
The launch of the Ranluspec ranibizumab biosimilar to Lucentis fills a gap in Sandoz’s portfolio while giving Lupin access to the European market.
Generics Bulletin - November 13, 2026
The launch of the Ranluspec ranibizumab biosimilar to Lucentis fills a gap in Sandoz’s portfolio while giving Lupin access to the European market.
Generics Bulletin - November 13, 2026
Special Episode: Topspin and Why Product Demand, Not Coverage, Drives Formulary Power
Formulary placement is rented real estate: PBMs keep products that generate prescription demand. Rebates mean little without volume, so pharma should start market access thinking in Phase II, not after filing.
In Vivo - November 13, 2026
Formulary placement is rented real estate: PBMs keep products that generate prescription demand. Rebates mean little without volume, so pharma should start market access thinking in Phase II, not after filing.
In Vivo - November 13, 2026
Preventive Medicine’s Bottleneck Is Not Science – It’s Economics
Gene therapies that could prevent or cure disease in a single dose are drawing billions in investment, but US and European health systems are built to pay for chronic care over a lifetime. Unless payers rethink incentives for one-time treatment, economics may set the pace more than science.
In Vivo - November 13, 2026
Gene therapies that could prevent or cure disease in a single dose are drawing billions in investment, but US and European health systems are built to pay for chronic care over a lifetime. Unless payers rethink incentives for one-time treatment, economics may set the pace more than science.
In Vivo - November 13, 2026